Literature DB >> 16762115

A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.

K D Ramaiah1, K N Vijay Kumar, E Hosein, P Krishnamoorthy, D J Augustin, K S Snehalatha, B Nanda, P K Das.   

Abstract

In the mass drug administrations (MDA) that form the principal strategy of the Global Programme to Eliminate Lymphatic Filariasis, treatment coverages of at least 65%-80% will be needed if the programme is to be successful. In the Indian state of Tamil Nadu, where treatment coverages were typically <65%, a comprehensive strategy of advocacy and communication, called the "communication for behavioural impact" (COMBI) campaign, has been developed and implemented, in an attempt to improve treatment coverage. This strategy combined advocacy, aimed at state-, district- and village-level administrations, with communication activities targeted at individual communities. The main aim was to alter the behaviour of many of those included in the rounds of MDA, so that they would be more likely to accept and consume the diethylcarbamazine tablets offered to them. The COMBI campaign had two variants, COMBI(+) and the more intensive COMBI(+ +), each of which has been implemented in six districts. Both the variants included the "personal selling" of treatment, via door-to-door visiting by a total of 113,500 filaria-prevention assistants. These assistants were able to visit 34%-49% of the households in each target community. In the COMBI(+ +) districts, up to 44% and 38% of households received information on lymphatic filariasis and its elimination via television commercials and posters, respectively. Overall, 78% of the villages in the COMBI(+ +) districts and 33% of those in the COMBI(+) districts were considered to have had good exposure to the communication campaign. At the end of this campaign about 30% more people (than pre-campaign) believed that lymphatic filariasis could be eliminated and many of those targeted considered lymphatic filariasis to be a dreadful disease, knew that a particular day had been designated "Filaria Day", and thought that the tablets offered in MDA should be consumed to prevent or eliminate the disease. Apparently as the result of the COMBI campaign, drug consumption increased, from 33% of those living in endemic communities, to 37% in the COMBI(+) districts and to 49% in the COMBI(+ +). Coverages as high as 65%-73% were recorded among those who had had the maximum exposure to the communication campaign. These results indicate that the COMBI campaign favourably changed the perception and behaviour of the people towards the elimination of lymphatic filariasis. The costs of the COMBI(+) and COMBI(+ +) strategies were only U.S.$0.002 and U.S.$0.009 per capita, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762115     DOI: 10.1179/136485906X105598

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  16 in total

1.  Community participation for malaria elimination in Tafea Province, Vanuatu: Part I. Maintaining motivation for prevention practices in the context of disappearing disease.

Authors:  Jo-An M Atkinson; Lisa Fitzgerald; Hilson Toaliu; George Taleo; Anna Tynan; Maxine Whittaker; Ian Riley; Andrew Vallely
Journal:  Malar J       Date:  2010-04-12       Impact factor: 2.979

2.  Defining research to improve health systems.

Authors:  Jan H F Remme; Taghreed Adam; Francisco Becerra-Posada; Catherine D'Arcangues; Michael Devlin; Charles Gardner; Abdul Ghaffar; Joachim Hombach; Jane F K Kengeya; Anthony Mbewu; Michael T Mbizvo; Zafar Mirza; Tikki Pang; Robert G Ridley; Fabio Zicker; Robert F Terry
Journal:  PLoS Med       Date:  2010-11-16       Impact factor: 11.069

3.  Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs.

Authors:  Paul T Cantey; Jonathan Rout; Grace Rao; John Williamson; LeAnne M Fox
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

4.  High coverage of mass drug administration for lymphatic filariasis in rural and non-rural settings in the Western Area, Sierra Leone.

Authors:  Mary H Hodges; Samuel J Smith; Daniel Fussum; Joseph B Koroma; Abdul Conteh; Mustapha Sonnie; Santigie Sesay; Yaobi Zhang
Journal:  Parasit Vectors       Date:  2010-12-16       Impact factor: 3.876

5.  Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Authors:  K D Ramaiah; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

6.  The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia.

Authors:  Alison Krentel; Kaye Wellings
Journal:  Parasit Vectors       Date:  2018-03-12       Impact factor: 3.876

Review 7.  A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa.

Authors:  Adam Silumbwe; Joseph Mumba Zulu; Hikabasa Halwindi; Choolwe Jacobs; Jessy Zgambo; Rosalia Dambe; Mumbi Chola; Gershom Chongwe; Charles Michelo
Journal:  BMC Public Health       Date:  2017-05-22       Impact factor: 3.295

8.  Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.

Authors:  Wilma A Stolk; Quirine A ten Bosch; Sake J de Vlas; Peter U Fischer; Gary J Weil; Ann S Goldman
Journal:  PLoS Negl Trop Dis       Date:  2013-01-03

9.  Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines.

Authors:  Maria Lourdes E Amarillo; Vicente Y Belizario; Jewel T Sadiang-Abay; Stephanie Anne M Sison; Ariane Marie S Dayag
Journal:  Parasit Vectors       Date:  2008-05-27       Impact factor: 3.876

Review 10.  A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis.

Authors:  Alison Krentel; Peter U Fischer; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.